Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2003

View Archived Issues

Central role identified for ghrelin in energy homeostasis

New porphyrin photosensitizers discovered by French team

Juvantia reports alpha2B-adrenoceptor antagonists and their use

Protein aggregation-inhibitory agents for use in dementia therapy

Novartis claims new CCR3 antagonists for asthma and other respiratory disorders

Italian researchers prepare and test antitumor gold complexes

Novel adenosine agonists for cardiovascular and other disorders covered by Bayer patent

New antiangiogenic bisphosphonates: preparation and uses

Merck presents imidazole-based cannabinoid CB1 antagonists with utility in obesity

Development highlights during 2002 at Pliva

Bisphosphonate has antitumor and apoptosis-inducing effects in hematopoietic tumor cells

New factor Xa inhibitors in early development at Bayer

Columbia and Quintiles establish Striant commercialization agreement

PolyHeme trial cleared to begin in severely injured trauma patients

Zoloft contraindication announced

Lundbeck acquires Synaptic

Ezetrol completes Europe's mutual recognition procedure

Unigene files NDA for Fortical

New indication for Arava recommended for approval

GlaxoSmithKline and Shionogi to copromote Valtrex and Zovirax in Japan

NIH licensing opportunity: anti-HIV agents targeting NCp7

Tecastemizole exerts antiinflammatory effects in nasal epithelial cells

Airways hyperresponsiveness in experimental asthma reduced by liposome-encapsulated budesonide

Specific, small-molecule inhibitor of IgE responses characterized at AAAAI meeting

NW-1029 possesses potent and long-lasting antinociceptive effects in inflammatory, neuropathic pain

Mechanism underlying antitumor/antiangiogenic effects of Panzem

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...